Roundtable II: Cost concerns for rheumatoid arthritis treatment.
Auslander
M
M
Bresloff
T
T
Clark
D L
DL
Hillman
D
D
Lewis
D L
DL
Martinez
L
L
Milgram
L
L
Newcomer
D
D
Nguyen
T
T
Rae
J
J
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000191:economics* / Q000276:immunology / Q000628:therapy; D003362:Cost-Benefit Analysis; D016207:Cytokines / Q000191:economics / Q000627:therapeutic use; D003657:Decision Making; D016527:Drug Costs; D006297:Health Services Accessibility; D006801:Humans; D000069285:Infliximab; D019458:Insurance Coverage; D018579:Patient Selection; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014481:United States
D000911:Antibodies, Monoclonal; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab